Zobrazeno 1 - 10
of 107
pro vyhledávání: '"J T, Roberts"'
Publikováno v:
Environmental Research Letters, Vol 9, Iss 1, p 014011 (2014)
Countries are known to follow diverse pathways of life expectancy and carbon emissions, but little is known about factors driving these dynamics. In this letter we estimate the cross-sectional economic, demographic and geographic drivers of consumpti
Externí odkaz:
https://doaj.org/article/09a5d58664a74d27b324427f70d0a8e3
Autor:
J. T. Roberts
Publikováno v:
Clinical Oncology. 17:514-523
This paper reviews the current status of systemic chemotherapy in the management of advanced and metastatic urothelial cancer. The activity of a number of single agents and combination drug regimens is discussed, and the small number of randomised-co
Publikováno v:
The British Journal of Radiology. 78:832-835
The present rapid worldwide expansion of particle radiotherapy services will inevitably have an impact on clinical practice within the UK. The most recent results of developmental trials using protons and carbon ions are impressive, with high cure ra
Autor:
John Graham, Graham M. Mead, P. A. Cook, M. Sokal, David P. Dearnaley, J. T. Roberts, Michael Cullen, Stan B. Kaye, Sophie D. Fosså, M. V. Williams, SP Stenning, S. J. Harland
Publikováno v:
British Journal of Cancer
Adjuvant BEP (bleomycin, etoposide, cisplatin) is effective treatment for high-risk clinical stage I (HRCS1) non-seminomatous germ cell tumours (NSGCT), but the known toxicities of etoposide, and the expansion of the HR group to any patient with vasc
Autor:
Yvonne Vergouwe, Laurence Collette, Sally P. Stenning, H. J. Keizer, J T Roberts, Ewout W. Steyerberg, R. de Wit, J. D. F. Habbema
Publikováno v:
British Journal of Cancer
British Journal of Cancer, 88, 843-847. Nature Publishing Group
British Journal of Cancer, 88, 843-847. Nature Publishing Group
We assessed the external validity of a prediction rule for nonseminomatous testicular cancer patients. The rule was developed to predict the probability of retroperitoneal metastases being benign (only necrosis/fibrosis) after chemotherapy treatment.
Autor:
David E. Neal, C Marsh, J. T. Roberts, K N Qureshi, John Lunec, J.K. Mellon, T. R. L. Griffiths, M.C. Robinson
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 51:1234-1240
Purpose: The prognostic value of p21 and p53 expression was evaluated for patients with muscle-invasive bladder cancer treated by radical radiotherapy. Methods and Materials: Sixty-eight paraffin-embedded sections from surgically resected tumors take
Autor:
S. J. Harland, Sally P. Stenning, E. Lallemand, Graham M. Mead, Michael Cullen, R T D Oliver, Peter M Wilkinson, Sophie D. Fosså, Alan Horwich, David P. Dearnaley, J. T. Roberts
Publikováno v:
British Journal of Cancer
The UK Medical Research Council conducted this trial of carboplatin chemotherapy in advanced seminoma to compare single agent carboplatin with a standard combination of etoposide with cisplatin. The use of single agent carboplatin was expected to be
Autor:
M. C. Parkinson, S. J. Harland, Graham M. Mead, J. T. Roberts, Sally P. Stenning, P. A. Cook, Alan Horwich, Sophie D. Fossa
Publikováno v:
Journal of Urology. 160:1353-1357
Purpose: We define a group of testis cancer patients who are at high risk for carcinoma in situ of the contralateral testis and, therefore, a second germ cell tumor.Materials and Methods: The histology was reviewed in 186 testis cancer patients who u
Autor:
Richard A Cowan, Martin J. Russell, Gareth Griffiths, Peter Harper, B. M. Uscinska, Mona Parmar, J. T. Roberts, S. J. Harland, P. Clark, Graham M. Mead
Publikováno v:
British Journal of Cancer
Transitional cell carcinomas may arise at any site within the urinary tract and are a source of considerable morbidity and mortality. In particular, patients with metastatic disease have a poor prognosis, with less than 5% alive at 5 years. A multice
Autor:
Alan Horwich, G. Read, Stan B. Kaye, S. P. Stenning, S. J. Harland, Gordon J. S. Rustin, Michael Cullen, Peter M Wilkinson, Sophie D. Fosså, R.T.D. Oliver, Graham M. Mead, J. T. Roberts, P. A. Cook
Publikováno v:
European Journal of Cancer. 33:1380-1387
Prognostic factors for 3-year progression-free survival (PFS) were defined in 286 patients with advanced seminoma treated with cisplatin-based chemotherapy at 10 European oncology units (no prior treatment: 236; prior radiotherapy: 50). Previously ir